View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2019	Mar. 24, 2020	Jun. 30, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	OptimizeRx Corp
Entity Central Index Key	0001448431
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	NV
Entity File Number	001-38543
Entity Public Float			$ 221,759,775
Entity Common Stock, Shares Outstanding		14,635,611

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets
Cash and cash equivalents	$ 18,852,680	$ 8,914,034
Accounts receivable, net	7,418,025	6,457,841
Prepaid expenses	871,043	360,146
Total Current Assets	27,141,748	15,732,021
Property and equipment, net	176,014	149,330
Other Assets
Goodwill	14,740,031	3,678,513
Technology assets, net	6,238,453	104,820
Patent rights, net	2,550,587	2,766,944
Right of use assets, net	559,863
Other intangible assets, net	5,151,102	2,387,303
Security deposits and other assets	80,727	235,647
Total Other Assets	29,320,763	9,173,227
TOTAL ASSETS	56,638,525	25,054,578
Current Liabilities
Accounts payable - trade	492,995	411,010
Accrued expenses	1,800,635	1,300,882
Revenue share payable	1,618,438	1,908,616
Current portion of lease liabilities	115,431
Contingent purchase price payable	1,500,000
Deferred revenue	580,014	610,625
Total Current Liabilities	6,107,513	4,231,133
Non-current Liabilities
Lease liabilities, net of current portion	448,753
Contingent purchase price payable, net of current portion	5,220,000	2,365,000
Total Non-Current Liabilities	5,668,753	2,365,000
Total Liabilities	11,776,266	6,596,133
Commitments and contingencies (See Note 15)
Stockholders' Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2019 and 2018,
Common stock, $0.001 par value, 166,666,667 shares authorized, 14,600,579 and 12,038,618 shares issued and outstanding at December 31, 2019 and 2018, respectively	14,601	12,039
Additional paid-in-capital	78,272,268	48,725,211
Accumulated deficit	(33,424,610)	(30,278,805)
Total Stockholders' Equity	44,862,259	18,458,445
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 56,638,525	$ 25,054,578

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	166,666,667	166,666,667
Common stock, shares issued	14,600,579	12,038,618
Common stock, shares outstanding	14,600,579	12,038,618

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2019	Dec. 31, 2018
NET REVENUE
Revenue	$ 24,598,274	$ 21,206,363
Cost of revenues	9,158,699	8,999,666
Gross margin	15,439,575	12,206,697
Operating expenses
Stock-based compensation	2,260,298	2,520,852
Depreciation and amortization	1,282,787	316,502
Other general and administrative expenses	15,590,054	9,189,211
Total operating expenses	19,133,139	12,026,565
(Loss) income from operations	(3,693,564)	180,132
Other income (expense)
Interest income	288,028	46,212
Change in fair value of contingent consideration	(635,000)
Total other (expense) income	(346,972)	46,212
Income (loss) before provision for income taxes	(4,040,536)	226,344
Income tax benefit	897,960
Net (loss) income	$ (3,142,576)	$ 226,344
Weighted average number of shares outstanding – basic	13,387,863	10,832,209
Weighted average number of shares outstanding – diluted	13,387,863	11,862,991
(Loss) income per share – basic	$ (0.23)	$ 0.02
(Loss) income per share – diluted	$ (0.23)	$ 0.02

Consolidated Statement of Stockholders' Equity - USD ($)	Common Stock	Stock Warrants	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2017	$ 9,773	$ 1,286,424	$ 35,287,464	$ (30,363,122)	$ 6,220,539
Balance, shares at Dec. 31, 2017	9,772,694
Cumulative effect of change in accounting principle related to revenue recognition				(142,027)	(142,027)
Stock-based Compensation Expense			1,863,911		1,863,911
Issuance of common stock for services	$ 51		656,883		656,934
Issuance of common stock for services, shares	51,494
Issuance of common stock for cash	$ 1,667		8,162,807		8,164,474
Issuance of common stock for cash, shares	1,666,669
Issuance of common stock for options exercised	$ 165		521,105		521,270
Issuance of common stock for options exercised, shares	165,169
Issuance of common stock for warrants exercised	$ 251	(1,286,424)	1,286,173
Issuance of common stock for warrants exercised, shares	251,046
Shares issued for acquisition	$ 31		499,969		500,000
Shares issued for acquisition, shares	30,638
Shares issued in payment of revenue share	$ 100		446,900		447,000
Shares issued in payment of revenue share, shares	100,000
Additional shares issued in connection with reverse split due to rounding	$ 1		(1)
Additional shares issued in connection with reverse split due to rounding, shares	908
Net income loss for the year				226,344	226,344
Balance at Dec. 31, 2018	$ 12,039		48,725,211	(30,278,805)	18,458,445
Balance, shares at Dec. 31, 2018	12,038,618
Cumulative effect of change in accounting principle related to lease accounting				(3,229)	(3,229)
Shares issued in 2019 for restricted stock awards granted and expensed in 2018	$ 130		(130)
Shares issued in 2019 for restricted stock awards granted and expensed in 2018, shares	130,001
Stock-based Compensation Expense Options			1,687,745		1,687,745
Stock-based Compensation Expense Restricted Stock			125,160		125,160
Issuance of common stock for services	$ 33		447,360		447,393
Issuance of common stock for services, shares	33,344
Issuance of common stock for cash	$ 1,769		21,302,057		21,303,826
Issuance of common stock for cash, shares	1,769,275
Issuance of common stock for options exercised	$ 247		877,455		877,702
Issuance of common stock for options exercised, shares	246,448
Shares issued for acquisition	$ 383		5,107,410		5,107,793
Shares issued for acquisition, shares	382,893
Net income loss for the year				(3,142,576)	(3,142,576)
Balance at Dec. 31, 2019	$ 14,601		$ 78,272,268	$ (33,424,610)	$ 44,862,259
Balance, shares at Dec. 31, 2019	14,600,579

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income for the period	$ (3,142,576)	$ 226,344
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	1,282,787	316,502
Noncash lease expense	107,656
Increase in bad debt reserve	80,000
Loss on disposal of assets		2,401
Stock-based compensation	2,260,298	2,520,845
Income tax benefit	(897,960)
Change in fair value of contingent consideration	635,000
Changes in:
Accounts receivable	(628,830)	(2,789,252)
Prepaid expenses and other assets	(343,838)	(319,754)
Accounts payable	(46,249)	(83,319)
Revenue share payable	(290,178)	730,810
Accrued expenses and other	(432,075)	226,535
Change in operating lease liabilities	(106,564)
Deferred revenue	(30,611)	(38,557)
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES	(1,660,796)	792,555
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(87,717)	(34,362)
Acquisition of intangible assets	(1,500,000)	(56,651)
Cash paid in acquisition, net of cash acquired	(8,994,369)	(5,595,820)
NET CASH USED IN INVESTING ACTIVITIES	(10,582,086)	(5,686,833)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of offering costs	21,303,826	8,164,475
Proceeds from exercise of stock options	877,702	521,264
NET CASH PROVIDED BY FINANCING ACTIVITIES	22,181,528	8,685,739
NET INCREASE IN CASH AND CASH EQUIVALENTS	9,938,646	3,791,461
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD	8,914,034	5,122,573
CASH AND CASH EQUIVALENTS – END OF PERIOD	18,852,680	8,914,034
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
Cash paid for income taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Exercise of stock warrants		1,286,424
Issuance of shares for restricted stock awards in 2019 for awards expensed in 2018	130
Lease liabilities arising from right of use assets	207,559
Common stock issued for debt		447,000
Shares issued in connection with acquisitions	5,107,793	500,000
Non-cash effect of cumulative adjustments to accumulated deficit	$ 3,229	$ 142,027

Organization and Nature of Business

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND NATURE OF BUSINESS

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

OptimizeRx Corporation is a digital health company focused on connecting life sciences companies to their clients with critical content at the point-of-care. It provides electronic clinical information via electronic health record companies (EHRs) to the medical profession, providing a direct channel for pharmaceutical companies to communicate with healthcare providers. The Company's cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, and critical clinical information. The Company's network is comprised of leading EHR platforms and provides more than half of the ambulatory patient market with access to these benefits within their workflow at the point-of-care.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the carrying value of assets, depreciable and amortizable lives of tangible and intangible assets, the carrying value of liabilities, the valuation allowance for the deferred tax asset, the timing of revenue recognition and related revenue share expenses, and inputs used in the calculation of stock based compensation. Actual results could differ from these estimates.

Principles of Consolidation

The financial statements reflect the consolidated results of OptimizeRx Corporation, a Nevada corporation, and its wholly owned subsidiaries: OptimizeRx Corporation, a Michigan corporation, RMDY Health, Inc., a Delaware corporation, CareSpeak Communications, Inc., a New Jersey corporation, Cyberdiet, a controlled foreign corporation incorporated in Israel, and CareSpeak Communications D.O.O., a Controlled Foreign Corporation incorporated in Croatia. Together, these companies are referred to as "OptimizeRx" and "the Company." All material intercompany transactions have been eliminated.

Reclassifications

Certain items in the previous year financial statements have been reclassified to match the current year presentation.

Cash and Cash Equivalents

For purposes of the accompanying financial statements, the Company considers all highly liquid instruments, consisting of money market accounts, with an initial maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk.

In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 – Inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Inputs are generally unobservable and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company's stock options and warrants are valued using level 3 inputs.

The following tables present the fair values and carrying values of the Company's financial assets and liabilities measured on a recurring basis as of December 31, 2019 and 2018 and the valuation techniques used by the Company to determine those fair values.

	2019
	Level 1		Level 2		Level 3		Fair Value		Carrying Value

Liabilities
Contingent Purchase Price Payable (1)	$	-	$	-	$	6,720,000	$	6,720,000	$	6,720,000

	2018
	Level 1		Level 2		Level 3		Fair Value		Carrying Value

Liabilities
Contingent Purchase Price Payable (1)	$	-	$	-	$	2,365,000	$	2,365,000	$	2,365,000

(1)

The contingent consideration is based off achieving certain revenue milestones in each of the next two years. The Geometric-Brownian motion analysis was used to generate spot prices for use in an option pricing model. For 2018, the hypothetical spot prices were simulated using a monte carlo simulation utilizing 2018 revenue as a base and revenue volatility of 37%. The risk-free rate of return and terms utilized were 2.89% and 1.46-2.46, respectively, and expected volatility was 35%. For 2019, the hypothetical spot prices were simulated using a monte carlo simulation utilizing 2020 and 2021 revenue projections and revenue volatility of 40%. The risk-free rate of return and terms utilized were 1.40% and 1 -2 years, respectively, and expected volatility was 40%.

The following table provides a summary of changes in fair value of the Company's Level 3 financial instruments for the years ended December 31, 2019 and 2018.

	Amount
Balance December 31, 2017	$	-
Contingent consideration liability recorded as the result of the CareSpeak Communications acquisition (see note 3)		2,365,000
Balance December 31, 2018		2,365,000
Increase in fair value of CareSpeak Communications contingent consideration		635,000
Contingent consideration liability recorded as the result of the RMDY Health, Inc. acquisition (see note 3)		3,720,000
Balance December 31, 2019	$	6,720,000

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Because the Company's customers are primarily large well-capitalized companies, historically there has been very little bad debt expense. Bad debt expense was $80,000 for the year ended December 31, 2019 and $0 for the year ended December 31, 2018. The allowance for doubtful accounts was $80,000 and $0 as of December 31, 2019 and 2018, respectively.

Property and Equipment

Property and equipment are stated at cost and are being depreciated over their estimated useful lives of three to five years for office equipment and three years for computer equipment using the straight-line method of depreciation for book purposes. Maintenance and repair charges are expensed as incurred.

Intangible Assets

Intangible assets are stated at cost. Finite-lived assets are being amortized over their estimated useful lives of fifteen to seventeen years for patents, eight years for customer relationships, fifteen years for tradenames, four years for covenants not to compete, and three to four years for software and websites, all using the straight-line method. These assets, as well as our indefinite-lived asset, are evaluated annually in our fiscal fourth quarter for impairment.

Goodwill

We evaluate goodwill for impairment during our fiscal fourth quarter, or more frequently if an event occurs or circumstances change.

Revenue Recognition

Recognition of revenue requires evidence of a contract, probable collection of proceeds, and completion of substantially all performance obligations. We use a 5-step model to recognize revenue. These steps are: identify the contract with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when or as the performance obligations are satisfied.

Revenues are primarily generated from content delivery activities in which the Company delivers financial, clinical, or brand messaging through a distribution network of eprescribers and electronic health record technology providers (channel partners), directly to consumers, or from reselling services that complement the business. Unless otherwise specified, revenue is recognized based on the gross selling price to customers.

The Company's contracts are generally all less than one year and the primary performance obligation is delivery of messages, but the contract may contain additional performance obligations. Additional performance obligations may include program design and set up, and reporting.

As the messaging is distributed through the platform and network of channel partners (a transaction), these transactions are recorded, and revenue is recognized, at the time of distribution. Revenue for transactions can be realized based on a price per message, a price per redemption, as a flat fee occurring over a period of time, or upon completion of the program, depending on the client contract. The Company recognizes setup fees that are required for integrating client offerings and campaigns into the rule-based content delivery system and network over the life of the initial program, based either on time, or units delivered, depending upon which is most appropriate in the specific situation. Should a program be cancelled before completion, the balance of set up revenue is recognized at the time of cancellation, as set up fees are nonrefundable. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance, either by the Company directly delivering reports or by providing access to its online reporting portal that the client can utilize. These fees are charged monthly and recognized as recurring monthly revenue at the time of delivery.

In some instances, the Company also resells products and or services that are available through channel partners on a commission basis, and that are complementary to the core business and client base. In these instances, net revenue is recognized based on the commission-based revenue split that the Company receives. In instances where the Company resells services and have all financial risk and significant operation input and risk, the Company records the revenue gross.

Cost of Revenues

The primary cost of revenue is revenue share expense. Based on the volume of transactions that are delivered through the channel partner network, the Company provides a revenue share to compensate the partner, or others, for their promotion of the campaign. Revenue shares are a negotiated percentage of the transaction fees and can also be specific to special considerations and campaigns.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

The Company recognizes the tax benefit from uncertain tax positions if it is more likely than not that the tax positions will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. It is the Company's policy to include interest and penalties related to tax positions as a component of income tax expense.

Concentration of Credit Risks

The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties. As of December 31, 2019 and 2018 the Company had $18,047,903 and $8,414,034, respectively, in cash balances in excess of federally insured limits, primarily at Bank of America/Merrill Lynch.

Research and Development

The Company expenses research and development expenses as incurred. Research and development expense was $1,604,195 and $0 in 2019 and 2018, respectively.

Stock-based Compensation

The Company uses the fair value method to account for stock-based compensation. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The fair value of each award is estimated on the date of each grant. For restricted stock, the fair market value is based on the market value of the stock granted on the date of the grant. For options, it is estimated using the Black-Scholes option pricing model that uses the assumptions noted in the following table. Estimated volatilities are based on the historical volatility of the Company's stock over the same period as the expected term of the options. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise behavior, forfeitures, and to determine this term. The risk-free rate used is based on the U.S. Treasury yield curve in effect at the time of the grant using a time period equal to the expected option term. The Company has never paid dividends and does not expect to pay any dividends in the future.

	2019			2018

Expected dividend yield		0	%		0	%
Risk free interest rate		1.51% - 2.37	%		1.96% - 2.84	%
Expected option term		3.5 years			3.5 - 5 years
Turnover/forfeiture rate		0	%		0	%
Expected volatility		64% - 67	%		64% - 66	%

The Black-Scholes option valuation model and other existing models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. These option valuation models require the input of, and are highly sensitive to, subjective assumptions including the expected stock price volatility. The Company's stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate.

(Loss) Earnings Per Common and Common Equivalent Share

The computation of basic (loss) earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted (loss) earnings per common share is based on the basic weighted average number of shares outstanding during the year plus common stock equivalents, which would arise from the exercise of options and warrants outstanding using the treasury stock method and the average market price per share during the year. The number of common shares potentially issuable upon the exercise of certain options that were excluded from the diluted loss per common share calculation in 2019 was 891,224 related to options, and 59,918 related to restricted stock, for a total of 951,142 because they are anti-dilutive, as a result of a net loss for the year ended December 31, 2019.

The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the years ended December 31, 2019 and 2018 consisted of the following:

	Net (Loss)			Shares		Per Share Amount
Year ended December 31, 2019
Basic EPS	$	(3,142,576	)		13,387,863	$	(0.23	)

Diluted EPS	$	(3,142,576	)		13,387,863	$	(0.23	)

	Net Income		Shares		Per Share Amount
Year ended December 31, 2018:
Basic EPS	$	226,344		10,832,209	$	0.02
Effect of dilutive stock options and warrants				1,030,782

Diluted EPS	$	226,344		11,862,991	$	0.02

Impairment of Long-Lived Assets

The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.

Recently Issued Accounting Guidance

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Under ASU No. 2016-02, the Company recognizes most leases on its balance sheet as lease liabilities with corresponding right-of-use assets. ASU No. 2016-02 was effective for fiscal years beginning after December 15, 2018. The Company adopted ASU No. 2016-02 on January 1, 2019. See Note 13 "Leases" for information regarding this standard and its adoption.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350). ASU No. 2017-04 was issued to simplify the accounting for goodwill impairment. ASU No. 2017-04 removes the second step of the goodwill impairment test, which requires that a hypothetical purchase price allocation be performed to determine the amount of impairment, if any. Under ASU No. 2017-04, a goodwill impairment charge will be based on the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU No. 2017-04 became effective on a prospective basis for the Company on January 1, 2020. The adoption of this standard did not have a material effect on the Company's financial position, results of operations or cash flows.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which introduces the Current Expected Credit Losses ("CECL") accounting model. CECL requires earlier recognition of credit losses, while also providing additional transparency about credit risk. CECL utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. ASU No. 2016-13 is effective for the Company on January 1, 2020. The adoption of this standard will not have a material effect on the Company's financial position, results of operations or cash flows.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to improve consistent application and simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance. ASU 2019-12 is effective for annual and interim reporting periods beginning after December 12, 2020, with early adoption permitted. We do not expect the adoption of ASU 2019-12 to have a material impact on our consolidated financial statements.

Acquisition

12 Months Ended

Dec. 31, 2019

Business Combinations [Abstract]

ACQUISITION

NOTE 3 – ACQUISITIONS

On October 17, 2018, we acquired CareSpeak Communications, Inc., a New Jersey corporation and technology solutions company, which provides digital messaging services to the healthcare industry to expand our service offerings. Through its cloud based Mobile Health Messenger ("MHM") Platform, CareSpeak provides interactive health messaging for improved medication adherence, care coordination, and patient engagement. The total purchase price was $8,493,451. Acquisition costs of approximately $607,670 were expensed as incurred.

The purchase price contains a contingent element that will be paid only if the Company achieves certain patient engagement revenues in 2019 and 2020. The total contingent payment may be up to $3.0 million. The target patient engagement revenues were achieved in 2019 and are expected to be achieved in 2020. The calculated fair value of the contingent payment is $3,000,000 at December 31, 2019.

Purchase Price Allocation

The purchase price of the CareSpeak acquisition was allocated as follows:

Purchase Price
Cash paid	$	5,628,451
Common stock issued		500,000
Contingent payment		2,365,000
Total	$	8,493,451

Allocation
Current assets	$	254,263
Property and equipment		8,487
Intangibles
Goodwill, including assembled workforce in place		3,678,513
Patent		2,227,000
Tradename		982,000
Non-compete agreements		977,000
Customer relationships		492,000
Current liabilities assumed		(125,812	)
Total	$	8,493,451

As described in greater detail in Note 6, the amortizable intangible assets acquired have estimated useful lives ranging from 4 to 15 years. We determined the estimated fair value of the identifiable intangible assets acquired primarily by using the income approach.

On October 4, 2019, we acquired RMDY Health, Inc. ("RMDY"), a Delaware corporation and technology solutions company engaged in developing and marketing digital health SAAS solutions across a range of healthcare and life science initiatives, used by pharmaceutical companies, payers, medtech companies, and medical associations nationwide to improve medication adherence and care coordination. The total purchase price was $17,822,162. Acquisition costs of approximately $799,623 were expensed as incurred.

The purchase price contains a contingent element that will be paid only if the Company achieves certain revenues related to the legacy RMDY business in 2020 and 2021. The total contingent payment may be up to $30.0 million, with a minimum payment of $1.0 million each year. The calculated fair value of the contingent payment is $3,720,000 at December 31, 2019.

The purchase price of the RMDY acquisition was allocated as follows:

Purchase Price
Cash paid	$	8,994,369
Common stock issued		5,107,793
Contingent payment		3,720,000
Total	$	17,822,162

Allocation
Current assets
Accounts receivable	$	411,354
Prepaid Expense		12,139
Property and equipment		19,173
Intangibles
Goodwill, including assembled workforce in place		11,061,518
Web technology		5,125,000
Tradename		2,604,000
Non-compete agreements		116,000
Customer relationships		431,000
Current liabilities assumed
Accounts payable		(128,234	)
Accrued expenses		(931,828	)
Deferred tax liability		(897,960	)
Total	$	17,822,162

As described in greater detail in Note 6, the amortizable intangible assets acquired have estimated useful lives ranging from 2 to 15 years. We determined the estimated fair value of the identifiable intangible assets acquired primarily by using the income approach.

Included in accrued expenses is $800,000 withheld at closing as part of an indemnification provision against potential future claims.

We began consolidating the results of CareSpeak operations and cashflows into our consolidated financial statements after October 17, 2018, the date of acquisition and the results of RMDY operations and cashflows after October 3, 2019, the date of that acquisition. The unaudited Pro forma results of operations as if both acquisitions had occurred January 1, 2018 are presented in the following table:

	2019						2018
	As Reported			Pro Forma			As Reported		Pro Forma
Revenues	$	24,598,278		$	26,118,278		$	21,206,363	$	24,520,995
Net (Loss) Income		(3,142,576	)		(3,869,577	)		226,344		(564,340	)
(Loss) Earnings per common share:
Basic	$	(0.23	)	$	(0.29	)	$	0.02	$	(0.05	)
Diluted	$	(0.23	)	$	(0.29	)	$	0.02	$	(0.05	)

Prepaid Expenses

12 Months Ended

Dec. 31, 2019

Prepaid Expenses [Abstract]

PREPAID EXPENSES

NOTE 4 – PREPAID EXPENSES

Prepaid expenses consisted of the following as of December 31, 2019 and 2018:

	2019		2018
Insurance	$	69,250	$	43,284
Prepaid revenue share payments		201,114		-
EHR access fees		313,121		302,527
Other		287,558		14,335
Total prepaid expenses	$	871,043	$	360,146

Property and Equipment

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 5 – PROPERTY AND EQUIPMENT

The Company owned equipment recorded at cost, which consisted of the following as of December 31, 2019 and 2018:

	2019		2018
Computer equipment	$	137,763	$	94,384
Furniture and fixtures		187,167		159,648
Subtotal		324,930		254,032
Less accumulated depreciation		148,916		104,702
Property and equipment, net	$	176,014	$	149,330

Depreciation expense was $80,206 and $58,423 for the years ended December 31, 2019 and 2018, respectively.

Intangible Assets

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 6 – INTANBIGLE ASSETS

Goodwill

The goodwill is related to the acquisition of RMDY Health, Inc. in 2019 and CareSpeak Communications in 2018 and is primarily related to expected improvements and technology performance and functionality, sales growth from future product and service offerings and new customers, together with certain intangible assets that do not qualify for separate recognition, such as the assembled workforce in place. Goodwill is generally not amortizable for tax purposes and is not amortizable for financial statement purposes.

Intangible Assets

Intangible assets included on the balance sheet consist of the following:

	December 31, 2019
	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Life Remaining
Patent rights	$	3,329,457	$	778,870	$	2,550,587	11.7
Technology Assets	$	8,140,013	$	1,901,560	$	6,238,453	8.0
Other intangible assets
Tradename	$	3,586,000	$	59,767	$	3,526,233	14.5
Non-compete agreements		1,093,000		309,635		783,365	2.7
Customer relationships		923,000		81,496		841,504	10.5
Total other		5,602,000		450,898		5,151,102
Total Intangibles	$	17,071,470	$	3,131,328	$	13,940,142

	December 31, 2018
	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Life Remaining
Patent rights	$	3,329,457	$	562,513	$	2,766,944	12.7
Technology assets	$	1,515,013	$	1,473,890	$	104,820	1.1
Other intangible assets
Tradename		982,000		-		982,000	Indefinite
Non-compete agreements		977,000		50,885		926,115	3.8
Customer relationships		492,000		12,812		479,188	7.8
Total other		2,451,000		63,697		2,387,303
Total Intangibles	$	7,295,470	$	2,036,403	$	5,259,067

Intangibles are being amortized on a straight-line basis over the following estimated useful lives.

Patents			15 – 17 years
Tradenames			15 years
Non-compete agreements			2 – 4 years
Customer relationships			8 – 15 years
Technology assets			3 – 10 years

The Company recorded amortization expense of $1,094,924 and $258,079 in the years ended December 31, 2019 and 2018, respectively. Expected future amortization expenses of the intangibles assets as of December 31, 2019 is as follows:

Year ended December 31,
2020	$	1,811,400
2021		1,794,795
2022		1,391,965
2023		990,267
2024		990,267
Thereafter		6,961,448
Total	$	13,940,142

In addition to the technology assets acquired in connection with the RMDY acquisition, the company also acquired software with a cost of $1.5 million in 2019.

Deferred Revenue

12 Months Ended

Dec. 31, 2019

Revenue Recognition [Abstract]

DEFERRED REVENUE

NOTE 7 – DEFERRED REVENUE

The Company has several signed contracts with customers for the distribution of financial messaging, or other services, which include payment in advance. The payments are not recorded as revenue until the revenue is earned under its revenue recognition policy discussed in Note 2. Deferred revenue was $580,014 and $610,625 as of December 31, 2019 and 2018, respectively.

Related Party Transactions

12 Months Ended

Dec. 31, 2019

RELATED PARTY TRANSACTIONS

NOTE 8 – RELATED PARTY TRANSACTIONS

During the year ended December 31, 2010, the Company acquired the technical contributions and assignment of all exclusive rights to and for a key patent in process at the time from a former CEO in exchange for a total payment in shares of common stock and options valued at $930,000 at the time, and recorded at that cost. That patent remains in Patents on the consolidated balance sheet as of December 31, 2019.

During the year ended December 31, 2015, WPP, plc made a strategic investment in the Company and owned approximately 20% of the outstanding shares of the Company until December 2018, when it sold the shares. As of December 31, 2018, WPP was no longer a related party, however the transactions between WPP and the Company while they were a related party are set forth in the table below. The Company considers the pharmaceutical companies being represented by WPP agencies to be its customers and it received no preferable pricing from WPP agencies as a result of its related party status.

The following table sets forth the activity between the Company and WPP for the year ended December 31 2018:

Total billings to WPP Agencies	$	6,217,735
Revenue recognized from WPP Agencies	$	6,527,051
Accounts receivable	$	2,051,532

Contingent Purchase Price

12 Months Ended

Dec. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

CONTINGENT PURCHASE PRICE

NOTE 9 – CONTINGENT PURCHASE PRICE

Our purchase of CareSpeak Communications contains a contingent element that will be paid only if the Company achieves certain patient engagement revenues in 2019 and 2020. The total contingent payment may be up to $3.0 million. The target patient engagement revenues were achieved in 2019 and are expected to be achieved in 2020. The calculated fair value of the contingent payment was $2,365,000 at December 31, 2018 and $3,000,000 at December 31, 2019.

Our purchase of RMDY Health, Inc. also contains a contingent element that will be paid only if the Company achieves certain revenues in 2020 and 2021 related to the RMDY business. The total contingent payment may be up to $30.0 million. The minimum payment is $1.0 million in each of the two years. The calculated fair value of the contingent payment was $3,720,000 at December 31, 2019. We determined the fair value of the Contingent Purchase Price Payable at December 31, 2019 using a Geometric-Brownian motion analysis of the expected revenue and resulting earnout payment using inputs that include the spot price, a risk free rate of return of 1.4%, a term of 2 years, and volatility of 40%. Changes in the inputs could result in a different fair value measurement.

The total fair value of contingent purchase price payable at December 31, 2019 is as follows.

	Current		Long-Term		Total
CareSpeak Communications, Inc.	$	1,500,000	$	1,500,000	$	3,000,000
RMDY Health, Inc.		-		3,720,000		3,720,000
Total	$	1,500,000	$	5,220,000	$	6,720,000

Stockholders' Equity

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 10 – STOCKHOLDERS' EQUITY

Preferred Stock

The Company has 10,000,000 shares of preferred stock, $.001 par value per share, authorized as of December 31, 2019. No shares were issued or outstanding in either 2018 or 2019.

Common Stock

The Company had 166,666,667 shares of common stock, $.001 par value per share, authorized as of December 31, 2019. There were 14,600,579 and 12,038,618 shares of common stock issued and outstanding at December 31, 2019 and 2018, respectively.

Effective May 14, 2018, in connection with our listing on the Nasdaq Capital Market, we implemented a reverse split of our common stock by exchanging each three shares of our common stock for one share. Our financial statements and all equity transactions have been retroactively adjusted to account for the reverse stock split. We elected to round fractional shares up to the nearest whole number rather than redeem them for cash, and as a result we issued 908 additional shares as a result of this rounding. In connection with this reverse split, our authorized shares were reduced from 500,000,000 to 166,666,667.

In 2018, we issued 100,000 shares of common stock to a subsidiary of WPP, one of the world's largest media companies, and a shareholder at the time, in full payment of all amounts due under a co-marketing agreement that covered certain WPP agencies, whereby we shared a portion of our revenue with those agencies related to new programs through those agencies. The shares were valued at $447,000, the market value of the stock on the date of issuance. The amount due was recorded as a liability in revenue share payable at December 31, 2017.

During 2019, in an underwritten public offering, we issued 1,769,275 shares of our common stock for gross proceeds of $23,000,575. In connection with this transaction, we incurred equity issuance costs of $1,696,749 related to payments to the underwriter, advisors and legal fees associated with the transaction, resulting in net proceeds to the Company of $21,303,826.

During 2018, in a private transaction, we issued 1,666,669 shares of our common stock for gross proceeds of $9,000,000. In connection with this transaction, we incurred equity issuance costs of $835,526 related to payments to advisors and legal fees associated with the transaction, resulting in net proceeds to the Company of $8,164,474.

The Company has a Director Compensation plan covering its independent non-employee Directors. A total of 33,344 and 36,494 shares were granted and issued in the years ended December 31, 2019 and 2018, respectively, in connection with this compensation plan. These shares were valued at $447,393 and $428,884, respectively. The Company also awarded 130,001 restricted stock awards, valued at $546,007, to executive officers in 2018. These awards would vest only if the Company achieved certain stretch revenue goals in 2018 or 2019. It was determined that the goal was achieved as of December 31, 2018, so the entire expense was recognized in 2018, but the shares related to these awards were issued in 2019.

During 2019, we issued 382,893 shares of common stock, valued at $5,107,793, to the former shareholders of RMDY Health, Inc. in connection with the acquisition of RMDY in 2019. We also issued 30,638 shares of common stock, valued at $500,000, to the former shareholders of CareSpeak Communications, Inc., in connection with the acquisition of the CareSpeak in 2018.

We issued 246,448 shares of common stock and received proceeds of $877,702 in 2019 in connection with the exercise of options. We also issued 165,169 shares of common stock and received proceeds of $521,270 in 2018 in connection with the exercise of options.

During 2018, we issued 15,000 shares of our common stock, valued at $228,050, for investor relations services.

During, 2018, we issued 251,046 shares of common stock in connection with the cashless exercise of a warrant to purchase 348,194 shares.

We adopted the new accounting standard ASC 606, Revenue from Contracts with Customers, as of January 1, 2018, which resulted in a charge of $142,027 to Retained Earnings on that date. We adopted the new lease accounting standard ASC 842 as of January 1, 2019, which resulted in a charge of $3,229 to Retained Earnings on that date.

Stock Compensation

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

STOCK COMPENSATION

NOTE 11 – STOCK COMPENSATION

The Company sponsors a stock-based incentive compensation plan known as the 2013 Equity Compensation Plan (the "Plan"), which was established by the Board of Directors of the Company in June 2013. A total of 500,000 shares were initially reserved for issuance under the Plan. The Plan was amended several times since then to eventually increase the authorized shares to 2,500,000 as of December 31, 2019. A total of 1,624,221 shares of common stock underlying options were outstanding at December 31, 2019. The Company had 236,614 remaining shares available to grant under the Plan at December 31, 2019.

The Plan allows the Company to grant incentive stock options, non-qualified stock options, stock appreciation rights, or restricted stock. The incentive stock options are exercisable for up to ten years, at an option price per share not less than the fair market value on the date the option is granted. The incentive stock options are limited to persons who are regular full-time employees of the Company at the date of the grant of the option. Non-qualified options may be granted to any person, including, but not limited to, employees, independent agents, consultants and attorneys, who the Company's Board or Compensation Committee believes have contributed, or will contribute, to the success of the Company. Non-qualified options may be issued at option prices of less than fair market value on the date of grant and may be exercisable for up to ten years from date of grant. The option vesting schedule for options granted is determined by the Compensation Committee of the Board of Directors at the time of the grant. The Plan provides for accelerated vesting of unvested options if there is a change in control, as defined in the Plan.

The compensation cost that has been charged against income related to options for the years ended December 31, 2019 and 2018, was $1,687,745 and $1,317,904, respectively. No income tax benefit was recognized in the income statement and no compensation was capitalized in any of the years presented.

The Company had the following option activity during the years ended December 31, 2019 and 2018:

	Number of Options			Weighted average exercise price		Weighted average remaining contractual life (years)		Aggregate intrinsic value $
Outstanding, January 1, 2018		1,368,772		$	3.12
Granted – 2018		401,099		$	9.27
Exercised – 2018		(165,169	)	$	3.16
Expired – 2018		(50,002	)	$	5.48
Outstanding, December 31, 2018		1,554,700		$	4.63		3.0
Granted – 2019		410,134		$	12.28
Exercised – 2019		(251,063	)	$	3.73
Expired – 2019		(89,550	)	$	12.55
Outstanding, December 31, 2019		1,624,221		$	6.27		2.6	$	7,925,643
Exercisable, December 31, 2019		1,143,637		$	4.39		1.9	$	7,197,053

Of the options outstanding at December 31, 2019, 1,143,637 were exercisable with a weighted average contractual life of 1.9 years.

The table below shows the expiration date and exercise price of the options outstanding at December 31, 2019.

Number of Options			Exercise Price		Expiration Date
	175,799		$	2.46	03/31/22
	41,668		$	3.15	06/24/20
	210,520		$	3.15	07/27/22
	470,000		$	3.21	02/22/21
	105,836		$	3.45	07/28/21
	100,006		$	4.20	02/01/23
	8,336		$	4.62	03/31/23
	8,336		$	4.71	12/31/22
	8,000		$	9.76	12/02/24
	139,000		$	10.18	11/24/24
	8,336		$	10.40	06/30/23
	11,800		$	12.49	08/13/23
	6,000		$	12.51	08/20/23
	10,000		$	12.70	08/22/23
	15,000		$	12.73	09/04/23
	14,084		$	12.77	04/08/24
	30,500		$	13.06	02/27/24
	16,000		$	13.31	06/10/24
	40,000		$	13.34	10/04/24
	29,000		$	14.48	09/30/24
	16,000		$	15.10	05/23/24
	12,000		$	15.32	0715/24
	125,000		$	15.40	10/16/23
	16,000		$	15.51	05/30/24
	7,000		$	16.24	10/22/23

	Total	1,624,221	$	6.27

There is $1,612,382 of expense remaining to be recognized over a period of approximately 1.8 years related to options outstanding at December 31, 2019.

In 2019, the Company granted restricted stock awards of 50,000 shares, valued at $653,000, which would vest if the Company achieved certain 2019 revenue targets. The Company did not achieve those targets, so the awards expired unvested on December 31, 2019. The Company also granted a restricted stock award of 90,000 shares, valued at $938,700, and vesting over a period of 5 years. The Company recognized $125,160 expense related to this award in 2019 and $813,540 remains to be recognized at December 31, 2019 over a period of 4.3 years.

The Company also awarded 130,001 restricted stock awards, valued at $546,007, in 2018. These awards would vest only if the Company achieved certain stretch revenue goals in 2018 or 2019. It was determined that the goal was achieved as of December 31, 2018, so the entire expense was recognized in 2018, but the shares related to these awards were issued in 2019.

Warrants

12 Months Ended

Dec. 31, 2019

Warrants [Abstract]

WARRANTS

NOTE 12 –WARRANTS

The Company has issued warrants to purchase common stock in the past, primarily in connection with capital raising activities. However, all remaining warrants were exercised in 2018 and there are no remaining warrants outstanding at December 31, 2018 or 2019.

The Company had the following warrant activity during the year ended December 31, 2018:

	Number of Shares Underlying Warrants			Weighted average exercise price
Balance, December 31, 2017		348,194		$	3.33
Exercised		(348,194	)	$	3.33
Balance, December 31, 2018		-			-

Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

LEASES

NOTE 13 – LEASES

In February 2016, the Financial Accounting Standards Board ("FASB") issued new accounting guidance on leases. The accounting standard, effective January 1, 2019, requires virtually all leases to be recognized on the balance sheet. Effective January 1, 2019, we adopted the standard using the modified retrospective method, under which we elected the package of practical expedients and transition provisions allowing us to bring our existing operating leases onto the consolidated balance sheet without adjusting comparative periods, but recognizing a cumulative-effect adjustment to the opening balance of accumulated deficit on January 1, 2019. Under the guidance, we have also elected not to separate lease and non-lease components in recognition of the lease-related assets and liabilities, as well as the related lease expense.

We have operating leases with terms greater than 12 months for office space in three multitenant facilities, which are recorded as assets and liabilities. The lease on our headquarters space in Rochester, Michigan expires November 30, 2022, with a three-year renewal option through 2025, with monthly rent payable at rates ranging from $6,384 to $6,688. We have assumed renewal of the lease. We also have a lease on office space in Cranbury, New Jersey, expiring in 2022 with monthly payments ranging from $3,008 to $3,158, as well as a lease of approximately $1,883 per month in Zagreb, Croatia expiring in 2022.

Lease-related assets, or right-of-use assets, are recognized at the lease commencement date at amounts equal to the respective lease liabilities, adjusted for prepaid lease payments, initial direct costs, and lease incentives received. Lease-related liabilities are recognized at the present value of the remaining contractual fixed lease payments, discounted using our incremental borrowing rate. Operating lease expense is recognized on a straight-line basis over the lease term, while variable lease payments are expensed as incurred.

Upon adoption of the standard on January 1, 2019, we recorded approximately $462,000 of right of use assets and $465,000 of lease-related liabilities, with the difference recorded in accumulated deficit as the cumulative effect of change in accounting principle at that date.

For the year ended December 31, 2019, the Company's lease cost consisted of the following components, each of which is included in operating expenses within the Company's consolidated statements of operations:

	Year Ended December 31, 2019

Operating lease cost	$	132,020
Short-term lease cost (1)		84,935
Total lease cost	$	216,955

(1) Short-term lease cost includes any lease with a term of less than 12 months.

The table below presents the future minimum lease payments to be made under operating leases as of December 31, 2019:

For the year ending December 31,
2020	$	138,019
2021		140,367
2022		102,367
2023		99,209
2024		80,375
Thereafter		70,224
Total		630,561
Less: present value discount		66,377
Total lease liabilities	$	564,184

The weighted average remaining lease term for operating leases is 5.1 years and the weighted average discount rate used in calculating the operating lease asset and liability is 4.5%. Cash paid for amounts included in the measurement of lease liabilities was $106,564. For the year ended December 31, 2019, payments on lease obligations were $132,867 and amortization on the right of use assets was $107,656.

Major Customers and Vendors

12 Months Ended

Dec. 31, 2019

Major Customers [Abstract]

MAJOR CUSTOMERS AND VENDORS

NOTE 14 – MAJOR CUSTOMERS AND VENDORS

The Company had the following customers that accounted for 10% or greater of revenue in either 2019 or 2018. No other customers accounted for more than 10% of revenue in either year presented.

	2019				2018
	$		%		$		%
Customer A		3,883,589		15.8		1,678,669		7.9
Customer B		2,801,748		11.4		930,682		4.4
Customer C		2,533,766		10.3		2,122,657		10.0
Customer D		1,349,214		5.5		2,547,113		12.0
Customer E		-		0		2,280,873		10.8

Our accounts receivable includes 3 customers that individually make up more than 10% of our accounts receivable at December 31, 2019 in the percentages of 17.8%, 15.4% and 13.3%.

The Company had four key partners through which 10% or greater of its revenue was generated in either 2019 or 2018 as set forth below. The amounts in the table below reflect the amount of revenue generated through those customers.

	2019				2018
	$		%		$		%
Partner A		1,315,706		5.3		6,841,386		32.3
Partner B		9,210,347		37.4		5,350,393		25.2
Partner C		4,051,217		16.5		2,584,103		12.2
Partner D		1,007,573		4.1		2,159,356		10.2

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 15 – INCOME TAXES

As of December 31, 2019, the Company had net operating loss carry-forwards for federal income tax purposes of approximately $18.3 million, consisting of pre-2018 losses in the amount of approximately $14.3 million that expire from 2020 through 2037, and post-2017 losses in the amount of approximately $4 million that never expire. These net operating losses are available to offset future taxable income. The Company was formed in 2006 as a limited liability company and changed to a corporation in 2007. Activity prior to incorporation is not reflected in the Company's corporate tax returns. In the future, the cumulative net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement loss due to timing differences between book and tax reporting.

The provision for Federal income tax consists of the following for the years ended December 31, 2019 and 2018:

	2019			2018
Federal income tax benefit (expense) attributable to:
Current operations	$	848,000		$	(48,000	)
Acquisition costs		(143,000	)		-
Change in fair value of contingent consideration		(133,000	)		-
Other permanent items		29,000			(36,000	)
Deferred Adjustment		(913,000	)		-
Valuation allowance		1,209,960			84,000
Net provision for federal income tax	$	897,960		$	-

	2019		2018

Current tax benefit (expense) - Federal	$	-	$	-
Deferred tax benefit (expense) - Federal		-		-
Adjustment of valuation allowance from business combination		897,960		-
Total tax benefit (expense) on income	$	897,960	$	-

The cumulative tax effect of significant items comprising our net deferred tax amount at the expected rate of 21% is as follows as of December 31, 2019 and 2018:

	2019			2018
Deferred tax asset attributable to:
Net operating loss carryover	$	3,839,000		$	2,290,000
Stock compensation		320,000			535,000
Intangible Assets		-			124,000
Other		36,000			3,000
Deferred tax asset	$	4,195,000		$	2,952,000

Deferred tax liabilities attributable to:
Fixed assets	$	(13,000	)	$	(5,000	)
Intangibles		(2,438,000	)		-
Other		(16,000	)		(9,000	)
Valuation allowance		(1,728,000	)		(2,938,000	)
Deferred tax liability	$	(4,195,000	)	$	(2,952,000	)

Net deferred tax asset	$	-		$	-

The ultimate realization of deferred tax assets is dependent upon the Company's ability to generate sufficient taxable income during the periods in which the net operating losses expire and the temporary differences become deductible. The Company has determined that there is significant uncertainty that the results of future operations and the reversals of existing taxable temporary differences will generate sufficient taxable income to realize the deferred tax assets; therefore, a valuation allowance has been recorded. In making this determination, the Company considered historical levels of income as well as projections for future periods.

The tax years 2016 to 2019 remain open for potential audit by the Internal Revenue Service. There are no uncertain tax positions as of December 31, 2018 or December 31, 2019, and none are expected in the next 12 months. The Company's foreign subsidiaries are cost centers that are reimbursed for expenses, so generate no income or loss. Pretax book income (loss) is all from domestic operations. Up to four years of returns remain open for potential audit in foreign jurisdictions, however any audits for periods prior to ownership by the Company are the responsibility of the previous owners.

Under certain circumstances issuance of common shares can result in an ownership change under Internal Revenue Code Section 382, which limits the Company's ability to utilize carry-forwards from prior to the ownership change. Any such ownership change resulting from stock issuances and redemptions could limit the Company's ability to utilize any net operating loss carry-forwards or credits generated before this change in ownership. These limitations can limit both the timing of usage of these laws, as well as the loss of the ability to use these net operating losses. It is likely that fundraising activities have resulted in such an ownership change.

Commitments and Contingent Liabilities

12 Months Ended

Dec. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

NOTE 16 – COMMITMENTS AND CONTINGENT LIABILITIES

Legal

The Company is not involved in any legal proceedings.

Revenue-share contracts

The Company has contacts with various electronic health records systems and ePrescribe platforms, whereby we agree to share a portion of the revenue we generate for eCoupons distributed through their networks. These contracts grant audit rights related to the payments to our partners, and, in some cases would require us to pay for the audit if the audit determined there was an underpayment and the underpayment meets certain thresholds, such as 10%. From time to time the Company enters into arrangements with a partner to acquire minimum amounts of messaging capabilities. As of December 31, 2019, the Company had had commitments for future minimum payments of $13.5 million that will be reflected in cost of revenues during the years from 2020 through 2022. Minimum payments are due in 2020, 2021, and 2022, in the amounts of $6.5 million, $5.5 million, and $2.0 million, respectively.

Retirement Plan

12 Months Ended

Dec. 31, 2019

Retirement Benefits [Abstract]

RETIREMENT PLAN

NOTE 17 – RETIREMENT PLAN

The Company sponsors a defined contribution 401(k) profit sharing plan which was adopted in December 2015, effective in January 2016. Under the terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee's payroll. There was expense of $126,557 and $172,107 recorded in 2019 and 2018, respectively, for company contributions to the plan.

Subsequent Events

12 Months Ended

Dec. 31, 2019

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 18 – SUBSEQUENT EVENTS

In March 2020, the Company's Board of Directors amended the 2013 Equity Compensation Plan to increase the number of shares authorized under the plan to 3.0 million shares. At the same time, the Company granted 84,746 shares of restricted common stock and options to purchase 233,049 shares of common stock to officers that vest over the balance of 2020. The Board also granted options to purchase 33,000 shares of common stock to a non-officer, that were fully vested at the time of grant and 38,000 time-based options to new employees.

In 2020, the company issued 35,032 shares and received proceeds of $112,151 in connection with the exercise of options.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

Use of Estimates

Principles of Consolidation

Reclassifications

Certain items in the previous year financial statements have been reclassified to match the current year presentation.

Cash and Cash Equivalents

Fair Value of Financial Instruments

Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

	2019
	Level 1		Level 2		Level 3		Fair Value		Carrying Value

Liabilities
Contingent Purchase Price Payable (1)	$	-	$	-	$	6,720,000	$	6,720,000	$	6,720,000

	2018
	Level 1		Level 2		Level 3		Fair Value		Carrying Value

Liabilities
Contingent Purchase Price Payable (1)	$	-	$	-	$	2,365,000	$	2,365,000	$	2,365,000

(1)

The following table provides a summary of changes in fair value of the Company's Level 3 financial instruments for the years ended December 31, 2019 and 2018.

	Amount
Balance December 31, 2017	$	-
Contingent consideration liability recorded as the result of the CareSpeak Communications acquisition (see note 3)		2,365,000
Balance December 31, 2018		2,365,000
Increase in fair value of CareSpeak Communications contingent consideration		635,000
Contingent consideration liability recorded as the result of the RMDY Health, Inc. acquisition (see note 3)		3,720,000
Balance December 31, 2019	$	6,720,000

Accounts Receivable and Allowance for Doubtful Accounts

Property and Equipment

Intangible Assets

Goodwill

We evaluate goodwill for impairment during our fiscal fourth quarter, or more frequently if an event occurs or circumstances change.

Revenue Recognition

Cost of Revenues

Income Taxes

Concentration of Credit Risks

Research and Development

The Company expenses research and development expenses as incurred. Research and development expense was $1,604,195 and $0 in 2019 and 2018, respectively.

Stock-based Compensation

	2019			2018

Expected dividend yield		0	%		0	%
Risk free interest rate		1.51% - 2.37	%		1.96% - 2.84	%
Expected option term		3.5 years			3.5 - 5 years
Turnover/forfeiture rate		0	%		0	%
Expected volatility		64% - 67	%		64% - 66	%

(Loss) Earnings Per Common and Common Equivalent Share

The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the years ended December 31, 2019 and 2018 consisted of the following:

	Net (Loss)			Shares		Per Share Amount
Year ended December 31, 2019
Basic EPS	$	(3,142,576	)		13,387,863	$	(0.23	)

Diluted EPS	$	(3,142,576	)		13,387,863	$	(0.23	)

	Net Income		Shares		Per Share Amount
Year ended December 31, 2018:
Basic EPS	$	226,344		10,832,209	$	0.02
Effect of dilutive stock options and warrants				1,030,782

Diluted EPS	$	226,344		11,862,991	$	0.02

Impairment of Long-Lived Assets

Recently Issued Accounting Guidance

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Schedule of financial assets and liabilities measured on a recurring basis

	2019
	Level 1		Level 2		Level 3		Fair Value		Carrying Value

Liabilities
Contingent Purchase Price Payable (1)	$	-	$	-	$	6,720,000	$	6,720,000	$	6,720,000

	2018
	Level 1		Level 2		Level 3		Fair Value		Carrying Value

Liabilities
Contingent Purchase Price Payable (1)	$	-	$	-	$	2,365,000	$	2,365,000	$	2,365,000

(1)

Schedule of changes in fair value of the Company’s Level 3 financial instruments

	Amount
Balance December 31, 2017	$	-
Contingent consideration liability recorded as the result of the CareSpeak Communications acquisition (see note 3)		2,365,000
Balance December 31, 2018		2,365,000
Increase in fair value of CareSpeak Communications contingent consideration		635,000
Contingent consideration liability recorded as the result of the RMDY Health, Inc. acquisition (see note 3)		3,720,000
Balance December 31, 2019	$	6,720,000

Schedule of expected dividends

	2019			2018

Expected dividend yield		0	%		0	%
Risk free interest rate		1.51% - 2.37	%		1.96% - 2.84	%
Expected option term		3.5 years			3.5 - 5 years
Turnover/forfeiture rate		0	%		0	%
Expected volatility		64% - 67	%		64% - 66	%

Schedule of weighted average shares outstanding and the basic and diluted earnings per common share

	Net (Loss)			Shares		Per Share Amount
Year ended December 31, 2019
Basic EPS	$	(3,142,576	)		13,387,863	$	(0.23	)

Diluted EPS	$	(3,142,576	)		13,387,863	$	(0.23	)

	Net Income		Shares		Per Share Amount
Year ended December 31, 2018:
Basic EPS	$	226,344		10,832,209	$	0.02
Effect of dilutive stock options and warrants				1,030,782

Diluted EPS	$	226,344		11,862,991	$	0.02

Acquisition (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of pro forma results of operations

	2019						2018
	As Reported			Pro Forma			As Reported		Pro Forma
Revenues	$	24,598,278		$	26,118,278		$	21,206,363	$	24,520,995
Net (Loss) Income		(3,142,576	)		(3,869,577	)		226,344		(564,340	)
(Loss) Earnings per common share:
Basic	$	(0.23	)	$	(0.29	)	$	0.02	$	(0.05	)
Diluted	$	(0.23	)	$	(0.29	)	$	0.02	$	(0.05	)

CareSpeak acquisition [Member]

Schedule of purchase price of the acquisition

Purchase Price
Cash paid	$	5,628,451
Common stock issued		500,000
Contingent payment		2,365,000
Total	$	8,493,451

Allocation
Current assets	$	254,263
Property and equipment		8,487
Intangibles
Goodwill, including assembled workforce in place		3,678,513
Patent		2,227,000
Tradename		982,000
Non-compete agreements		977,000
Customer relationships		492,000
Current liabilities assumed		(125,812	)
Total	$	8,493,451

RMDY acquisition [Member]

Schedule of purchase price of the acquisition

Purchase Price
Cash paid	$	8,994,369
Common stock issued		5,107,793
Contingent payment		3,720,000
Total	$	17,822,162

Allocation
Current assets
Accounts receivable	$	411,354
Prepaid Expense		12,139
Property and equipment		19,173
Intangibles
Goodwill, including assembled workforce in place		11,061,518
Web technology		5,125,000
Tradename		2,604,000
Non-compete agreements		116,000
Customer relationships		431,000
Current liabilities assumed
Accounts payable		(128,234	)
Accrued expenses		(931,828	)
Deferred tax liability		(897,960	)
Total	$	17,822,162

Prepaid Expenses (Tables)

12 Months Ended

Dec. 31, 2019

Prepaid Expenses [Abstract]

Schedule of prepaid expenses

	2019		2018
Insurance	$	69,250	$	43,284
Prepaid revenue share payments		201,114		-
EHR access fees		313,121		302,527
Other		287,558		14,335
Total prepaid expenses	$	871,043	$	360,146

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	2019		2018
Computer equipment	$	137,763	$	94,384
Furniture and fixtures		187,167		159,648
Subtotal		324,930		254,032
Less accumulated depreciation		148,916		104,702
Property and equipment, net	$	176,014	$	149,330

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

	December 31, 2019
	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Life Remaining
Patent rights	$	3,329,457	$	778,870	$	2,550,587	11.7
Technology Assets	$	8,140,013	$	1,901,560	$	6,238,453	8.0
Other intangible assets
Tradename	$	3,586,000	$	59,767	$	3,526,233	14.5
Non-compete agreements		1,093,000		309,635		783,365	2.7
Customer relationships		923,000		81,496		841,504	10.5
Total other		5,602,000		450,898		5,151,102
Total Intangibles	$	17,071,470	$	3,131,328	$	13,940,142

	December 31, 2018
	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Life Remaining
Patent rights	$	3,329,457	$	562,513	$	2,766,944	12.7
Technology assets	$	1,515,013	$	1,473,890	$	104,820	1.1
Other intangible assets
Tradename		982,000		-		982,000	Indefinite
Non-compete agreements		977,000		50,885		926,115	3.8
Customer relationships		492,000		12,812		479,188	7.8
Total other		2,451,000		63,697		2,387,303
Total Intangibles	$	7,295,470	$	2,036,403	$	5,259,067

Schedule of intangibles estimated useful lives

Patents			15 - 17 years
Tradenames			15 years
Non-compete agreements			2 - 4 years
Customer relationships			8 - 15 years
Technology assets			3 - 10 years

Schedule of future amortization expenses of intangibles assets

Year ended December 31,
2020	$	1,811,400
2021		1,794,795
2022		1,391,965
2023		990,267
2024		990,267
Thereafter		6,961,448
Total	$	13,940,142

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of sets forth the activity between the Company and WPP

Total billings to WPP Agencies	$	6,217,735
Revenue recognized from WPP Agencies	$	6,527,051
Accounts receivable	$	2,051,532

Contingent Purchase Price (Tables)

12 Months Ended

Dec. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

fair value of contingent purchase price payable

	Current		Long-Term		Total
CareSpeak Communications, Inc.	$	1,500,000	$	1,500,000	$	3,000,000
RMDY Health, Inc.		-		3,720,000		3,720,000
Total	$	1,500,000	$	5,220,000	$	6,720,000

Stock Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Schedule of option activity

	Number of Options			Weighted average exercise price		Weighted average remaining contractual life (years)		Aggregate intrinsic value $
Outstanding, January 1, 2018		1,368,772		$	3.12
Granted – 2018		401,099		$	9.27
Exercised – 2018		(165,169	)	$	3.16
Expired – 2018		(50,002	)	$	5.48
Outstanding, December 31, 2018		1,554,700		$	4.63		3.0
Granted – 2019		410,134		$	12.28
Exercised – 2019		(251,063	)	$	3.73
Expired – 2019		(89,550	)	$	12.55
Outstanding, December 31, 2019		1,624,221		$	6.27		2.6	$	7,925,643
Exercisable, December 31, 2019		1,143,637		$	4.39		1.9	$	7,197,053

Schedule of expiration date and exercise price of the options outstanding

Number of Options			Exercise Price		Expiration Date
	175,799		$	2.46	03/31/22
	41,668		$	3.15	06/24/20
	210,520		$	3.15	07/27/22
	470,000		$	3.21	02/22/21
	105,836		$	3.45	07/28/21
	100,006		$	4.20	02/01/23
	8,336		$	4.62	03/31/23
	8,336		$	4.71	12/31/22
	8,000		$	9.76	12/02/24
	139,000		$	10.18	11/24/24
	8,336		$	10.40	06/30/23
	11,800		$	12.49	08/13/23
	6,000		$	12.51	08/20/23
	10,000		$	12.70	08/22/23
	15,000		$	12.73	09/04/23
	14,084		$	12.77	04/08/24
	30,500		$	13.06	02/27/24
	16,000		$	13.31	06/10/24
	40,000		$	13.34	10/04/24
	29,000		$	14.48	09/30/24
	16,000		$	15.10	05/23/24
	12,000		$	15.32	0715/24
	125,000		$	15.40	10/16/23
	16,000		$	15.51	05/30/24
	7,000		$	16.24	10/22/23

	Total	1,624,221	$	6.27

Warrants (Tables)

12 Months Ended

Dec. 31, 2019

Warrants [Abstract]

Schedule of warrant activity

	Number of Shares Underlying Warrants			Weighted average exercise price
Balance, December 31, 2017		348,194		$	3.33
Exercised		(348,194	)	$	3.33
Balance, December 31, 2018		-			-

Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Schedule of lease cost

	Year Ended December 31, 2019

Operating lease cost	$	132,020
Short-term lease cost (1)		84,935
Total lease cost	$	216,955

(1) Short-term lease cost includes any lease with a term of less than 12 months.

Schedule of future minimum lease payments

For the year ending December 31,
2020	$	138,019
2021		140,367
2022		102,367
2023		99,209
2024		80,375
Thereafter		70,224
Total		630,561
Less: present value discount		66,377
Total lease liabilities	$	564,184

Major Customers and Vendors (Tables)

12 Months Ended

Dec. 31, 2019

Customers [Member]

Schedule of accounted percentage of revenue

	2019				2018
	$		%		$		%
Customer A		3,883,589		15.8		1,678,669		7.9
Customer B		2,801,748		11.4		930,682		4.4
Customer C		2,533,766		10.3		2,122,657		10.0
Customer D		1,349,214		5.5		2,547,113		12.0
Customer E		-		0		2,280,873		10.8

Key Partners [Member]

Schedule of accounted percentage of revenue

	2019				2018
	$		%		$		%
Partner A		1,315,706		5.3		6,841,386		32.3
Partner B		9,210,347		37.4		5,350,393		25.2
Partner C		4,051,217		16.5		2,584,103		12.2
Partner D		1,007,573		4.1		2,159,356		10.2

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Schedule of federal income tax benefit

	2019			2018
Federal income tax benefit (expense) attributable to:
Current operations	$	848,000		$	(48,000	)
Acquisition costs		(143,000	)		-
Change in fair value of contingent consideration		(133,000	)		-
Other permanent items		29,000			(36,000	)
Deferred Adjustment		(913,000	)		-
Valuation allowance		1,209,960			84,000
Net provision for federal income tax	$	897,960		$	-

	2019		2018

Current tax benefit (expense) - Federal	$	-	$	-
Deferred tax benefit (expense) - Federal		-		-
Adjustment of valuation allowance from business combination		897,960		-
Total tax benefit (expense) on income	$	897,960	$	-

Schedule of deferred tax assets

	2019			2018
Deferred tax asset attributable to:
Net operating loss carryover	$	3,839,000		$	2,290,000
Stock compensation		320,000			535,000
Intangible Assets		-			124,000
Other		36,000			3,000
Deferred tax asset	$	4,195,000		$	2,952,000

Deferred tax liabilities attributable to:
Fixed assets	$	(13,000	)	$	(5,000	)
Intangibles		(2,438,000	)		-
Other		(16,000	)		(9,000	)
Valuation allowance		(1,728,000	)		(2,938,000	)
Deferred tax liability	$	(4,195,000	)	$	(2,952,000	)

Net deferred tax asset	$	-		$	-

Summary of Significant Accounting Policies (Details) - USD ($)

Dec. 31, 2019

Dec. 31, 2018

Liabilities

Contingent Purchase Price Payable

^[1]

$ 6,720,000

$ 2,365,000

Fair Value, Measurements, Recurring [Member]

Liabilities

Contingent Purchase Price Payable

^[1]

6,720,000

2,365,000

Fair Value Inputs Level 1 [Member] | Fair Value, Measurements, Recurring [Member]

Liabilities

Contingent Purchase Price Payable

^[1]

Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]

Liabilities

Contingent Purchase Price Payable

^[1]

Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]

Liabilities

Contingent Purchase Price Payable

^[1]

$ 6,720,000

$ 2,365,000

[1]

The contingent consideration is based off achieving certain revenue milestones in each of the next two years. The Geometric-Brownian motion analysis was used to generate spot prices for use in an option pricing model. For 2018, the hypothetical spot prices were simulated using a monte carlo simulation utilizing 2018 revenue as a base and revenue volatility of 37%. The risk-free rate of return and terms utilized were 2.89% and 1.46-2.46, respectively and expected volatility was 35%. For 2019, the hypothetical spot prices were simulated using a monte carlo simulation utilizing 2020 and 2021 revenue projections and revenue volatility of 40%. The risk-free rate of return and terms utilized were 1.40% and 1 -2 years, respectively and expected volatility was 40%.

Summary of Significant Accounting Policies (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Summary Of Significant Accounting Policies [Line Items]
Balance	$ 2,365,000
Contingent consideration liability recorded as the result of the CareSpeak Communications acquisition (see note 3)		2,365,000
Balance		2,365,000
Fair Value, Inputs, Level 3 [Member]
Summary Of Significant Accounting Policies [Line Items]
Balance	635,000
Contingent consideration liability recorded as the result of the CareSpeak Communications acquisition (see note 3)	3,720,000
Balance	$ 6,720,000	$ 635,000

Summary of Significant Accounting Policies (Details 2)	12 Months Ended
Summary of Significant Accounting Policies (Details 2)	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected dividend yield	0.00%	0.00%
Risk free interest rate minimum	1.51%	1.96%
Risk free interest rate maximum	2.37%	2.84%
Expected option term	3 years 6 months
Turnover/forfeiture rate	0.00%	0.00%
Expected volatility minimum	64.00%	64.00%
Expected volatility maximum	67.00%	66.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected option term		5 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected option term		3 years 6 months

Summary of Significant Accounting Policies (Details 3) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Basic EPS, Net Income	$ (3,142,576)	$ 226,344
Diluted EPS, Net Income	$ (3,142,576)	$ 226,344
Basic EPS, Shares	13,387,863	10,832,209
Effect of dilutive stock options and warrants, shares		1,030,782
Diluted EPS, Shares	13,387,863	11,862,991
Basic EPS, Per Share Amount	$ (0.23)	$ 0.02
Diluted EPS, Per Share Amount	$ (0.23)	$ 0.02

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Summary Of Significant Accounting Policies [Line Items]
Bad debt expense	$ 80,000
Allowance for doubtful accounts	80,000	0
Research and development expense	$ 1,604,195	0
Number of common shares potentially issuable upon the exercise of certain options and warrants	891,224
Cash balances for insured limits	$ 18,047,903	$ 8,414,034
Increase in deferred revenue	$ (3,229)
Contingent consideration, description	The hypothetical spot prices were simulated using a monte carlo simulation utilizing 2018 revenue as a base and revenue volatility of 37%. The risk-free rate of return and terms utilized were 2.89% and 1.46-2.46, respectively and expected volatility was 35%. For 2019, the hypothetical spot prices were simulated using a monte carlo simulation utilizing 2020 and 2021 revenue projections and revenue volatility of 40%. The risk-free rate of return and terms utilized were 1.40% and 1 -2 years, respectively and expected volatility was 40%.
Percentage of realized upon ultimate settlement	50.00%
Restricted stock	951,142
Restricted Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Restricted stock	59,918

Acquisition (Details) - USD ($)	12 Months Ended
Acquisition (Details) - USD ($)	Oct. 04, 2020	Dec. 31, 2019	Dec. 31, 2018
Accrued expenses		$ (1,800,635)	$ (1,300,882)
CareSpeak acquisition [Member]
Cash paid		5,628,451
Common stock issued		500,000
Contingent payment		2,365,000
Total		8,493,451
Current assets		254,263
Property and equipment		8,487
Intangibles
Current liabilities assumed		(125,812)
Total		8,493,451
CareSpeak acquisition [Member] \| Goodwill [Member]
Intangibles		3,678,513
CareSpeak acquisition [Member] \| Patent [Member]
Intangibles		2,227,000
CareSpeak acquisition [Member] \| Trade Name [Member]
Intangibles		982,000
CareSpeak acquisition [Member] \| Non-compete Agreements [Member]
Intangibles		977,000
CareSpeak acquisition [Member] \| Customer relationships [Member]
Intangibles		492,000
RMDY acquisition [Member]
Cash paid		8,994,369
Common stock issued		5,107,793
Contingent payment		3,720,000
Total	$ 17,822,162	17,822,162
Accounts receivable		411,354
Prepaid Expense		12,139
Property and equipment		19,173
Intangibles
Current liabilities assumed		(1,060,062)
Accounts payable		(128,234)
Accrued expenses		(128,234)
Deferred tax liability		(897,960)
Total		17,822,162
RMDY acquisition [Member] \| Goodwill [Member]
Intangibles		11,061,518
RMDY acquisition [Member] \| Non-compete Agreements [Member]
Intangibles		116,000
RMDY acquisition [Member] \| Customer relationships [Member]
Intangibles		431,000
RMDY acquisition [Member] \| Web technology [Member]
Intangibles		5,125,000
RMDY acquisition [Member] \| Tradename [Member]
Intangibles		$ 2,604,000

Acquisition (Details 1) - USD ($)	12 Months Ended
Acquisition (Details 1) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 24,598,274	$ 21,206,363
Net (Loss) Income	$ (4,040,536)	$ 226,344
(Loss) Earnings per common share:
Basic	$ (0.23)	$ 0.02
Diluted	$ (0.23)	$ 0.02
Pro Forma [Member]
Revenues	$ 26,118,278	$ 24,520,995
Net (Loss) Income	$ (3,869,577)	$ (564,340)
(Loss) Earnings per common share:
Basic	$ (0.29)	$ (0.05)
Diluted	$ (0.29)	$ (0.05)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Acquisition (Details Textual) - USD ($)	12 Months Ended
Acquisition (Details Textual) - USD ($)	Oct. 04, 2020	Dec. 31, 2019	Oct. 04, 2019
Acquisition (Textual)
Total contingent payment		$ 3,720,000
Fair value of contingent payment		$ 3,000,000
Estimated useful lives, description		Estimated useful lives ranging from 4 to 15 years.
Accrued expenses		$ 800,000
CareSpeak acquisition [Member]
Acquisition (Textual)
Total purchase price		8,493,451
Total contingent payment		3,000,000
RMDY acquisition [Member]
Acquisition (Textual)
Total purchase price	$ 17,822,162	17,822,162
Acquisition costs			$ 799,623
Total contingent payment		30,000,000
RMDY acquisition [Member] \| Minimum [Member]
Acquisition (Textual)
Total contingent payment		$ 1,000,000

Prepaid Expenses (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Prepaid Expenses [Abstract]
Insurance	$ 69,250	$ 43,764
Prepaid revenue share payments	201,114
EHR access fees	313,121	302,527
Other	287,558	14,335
Total prepaid expenses	$ 871,043	$ 360,146

Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal	$ 324,930	$ 254,032
Less accumulated depreciation	148,916	104,702
Property and equipment, net	176,014	149,330
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal	137,763	94,384
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal	$ 187,167	$ 159,648

Property and Equipment (Details Textual) - USD ($)	12 Months Ended
Property and Equipment (Details Textual) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property and Equipment (Textual)
Depreciation expense	$ 80,206	$ 58,423

Intangible Assets (Details) - USD ($)	12 Months Ended
Intangible Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 17,071,470	$ 7,295,470
Accumulated Amortization	3,131,328	2,036,403
Intangible assets , Net	2,550,587	2,766,944
Technology Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	8,140,013	1,515,013
Accumulated Amortization	1,901,560	1,473,890
Intangible assets , Net	$ 6,238,453	104,820
Weighted Average Life Remaining	8 years
Patent rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 3,329,457	3,329,457
Accumulated Amortization	778,870	562,513
Intangible assets , Net	$ 2,550,587	$ 2,766,944
Weighted Average Life Remaining	11 years 8 months 12 days	12 years 8 months 12 days
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 3,586,000	$ 982,000
Accumulated Amortization	59,767
Intangible assets , Net	$ 3,526,233	$ 982,000
Weighted Average Life Remaining	14 years 6 months
Weighted Average Life Remaining, Indefinite		Indefinite
Non-compete agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 1,093,000	$ 977,000
Accumulated Amortization	309,635	50,885
Intangible assets , Net	$ 783,365	$ 926,115
Weighted Average Life Remaining	2 years 8 months 12 days	3 years 9 months 18 days
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 923,000	$ 492,000
Accumulated Amortization	81,496	12,812
Intangible assets , Net	$ 841,504	$ 479,188
Weighted Average Life Remaining	10 years 6 months	7 years 9 months 18 days
Other intangible assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 5,602,000
Accumulated Amortization	450,898
Intangible assets , Net	$ 5,151,102
Web-Based Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life Remaining		1 year 1 month 6 days

Intangible Assets (Details 1)	12 Months Ended
Intangible Assets (Details 1)	Dec. 31, 2019
Maximum [Member] \| Technology Assets [Member]
Intangibles amortized estimated useful lives	10 years
Minimum [Member] \| Technology Assets [Member]
Intangibles amortized estimated useful lives	3 years
Patents [Member] \| Maximum [Member]
Intangibles amortized estimated useful lives	15 years
Patents [Member] \| Minimum [Member]
Intangibles amortized estimated useful lives	17 years
Tradename [Member]
Intangibles amortized estimated useful lives	15 years
Non-compete agreements [Member] \| Maximum [Member]
Intangibles amortized estimated useful lives	4 years
Non-compete agreements [Member] \| Minimum [Member]
Intangibles amortized estimated useful lives	2 years
Customer relationships [Member] \| Maximum [Member]
Intangibles amortized estimated useful lives	15 years
Customer relationships [Member] \| Minimum [Member]
Intangibles amortized estimated useful lives	8 years

Intangible Assets (Details 2) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Year ended December 31,
2020	$ 1,811,400
2021	1,794,795
2022	1,391,965
2023	990,267
2024	990,267
Thereafter	6,961,448
Total	$ 2,550,587	$ 2,766,944

Intangible Assets (Details Textual) - USD ($)	12 Months Ended
Intangible Assets (Details Textual) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Intangible Assets (Textual)
Amortization expense	$ 1,094,924	$ 258,079
Acquired software cost	$ 1,500,000

Deferred Revenue (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Deferred Revenue (Textual)
Deferred revenue	$ 580,014	$ 610,625

Related Party Transactions (Details)	12 Months Ended
Related Party Transactions (Details)	Dec. 31, 2018 USD ($)
Total billings to WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions	$ 6,217,735
Revenue recognized from WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions	6,527,051
Accounts receivable [Member]
Related Party Transaction [Line Items]
Related party transactions	$ 2,051,532

Related Party Transactions (Details Textual) - Chief Executive Officer [Member] - USD ($)	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2015
Related Party Transactions (Textual)
Common stock options	$ 930,000
Percentage of ownership by WPP		20.00%

Contingent Purchase Price (Details)	12 Months Ended
Contingent Purchase Price (Details)	Dec. 31, 2019 USD ($)
Total	$ 6,720,000
Current [Member]
Total	1,500,000
Long-Term [Member]
Total	5,220,000
CareSpeak Communications, Inc. [Member]
Total	3,000,000
CareSpeak Communications, Inc. [Member] \| Current [Member]
Total	1,500,000
CareSpeak Communications, Inc. [Member] \| Long-Term [Member]
Total	1,500,000
RMDY Health, Inc. [Member]
Total	3,720,000
RMDY Health, Inc. [Member] \| Current [Member]
Total
RMDY Health, Inc. [Member] \| Long-Term [Member]
Total	$ 3,720,000

Contingent Purchase Price (Details Textual) - USD ($)	12 Months Ended
Contingent Purchase Price (Details Textual) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Contingent Purchase Price (Textual)
Contingent purchase price payable	$ 5,220,000	$ 2,365,000
Risk free rate of return	1.40%
Fair value of term	2 years
Fair value of volatility	40.00%
Total contingent payment	$ 300,000
Minimum payment	1,000,000
Fair value of the contingent payment	$ 3,720,000

Stockholders' Equity (Details) - USD ($)		12 Months Ended
Stockholders' Equity (Details) - USD ($)	May 14, 2018	Dec. 31, 2019	Dec. 31, 2018
Equity (Textual)
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred Stock, par value		$ 0.001	$ 0.001
Preferred stock, shares issued
Preferred stock, shares outstanding
Shares of common stock issued, value		$ 21,303,826	$ 8,164,474
Payments to advisors and legal fees		1,696,749	835,526
Net proceeds issuance of common stock		21,303,826	8,164,474
Common stock value issued for services		447,393	656,934
Common stock acquisition, value		5,107,793	$ 500,000
Issued shares of common stock in connection with cashless exercise			251,046
Warrant to purchase shares			348,194
Stock-based compensation		$ 2,260,298	$ 2,520,845
Issuance of common stock exercise		246,448	165,169
Issuance of common stock exercise value		$ 877,702	$ 521,270
Reserve stock split, description	We implemented a reverse split of our common stock by exchanging each three shares of our common stock for one share.
Retained Earnings amount		3,229
Shares issued	908
Restricted stock awards value		$ 653,000	$ 546,007
Restricted stock awards shares		50,000	130,001
Common stock, par value		$ 0.001	$ 0.001
Common stock, shares authorized		166,666,667	166,666,667
Common stock, shares issued		14,600,579	12,038,618
Common stock, shares outstanding		14,600,579	12,038,618
Maximum [Member]
Equity (Textual)
Common stock, shares authorized	166,666,667
Minimum [Member]
Equity (Textual)
Common stock, shares authorized	500,000,000
Private Transaction [Member]
Equity (Textual)
Shares of common stock issued		1,769,275	1,666,669
Gross proceeds of common stock amount		$ 23,000,575	$ 9,000,000
Subsidiary of WPP [Member]
Equity (Textual)
Shares of common stock issued		100,000
Shares of common stock issued, value		$ 447,000
RMDY Health, Inc. [Member]
Equity (Textual)
Shares of common stock issued		382,893	30,638
Shares of common stock issued, value		$ 5,107,793	$ 500,000
Directors [Member]
Equity (Textual)
Shares of common stock issued, value		$ 447,393	$ 428,884
Compensation plan issuance of shares		33,344	36,494
Investor [Member]
Equity (Textual)
Common stock value issued for services		$ 228,050
Common stock shares issued for services, shares		15,000

Stock Compensation (Details) - Stock Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of Options
Begining balance, Outstanding	1,554,700	1,368,772
Granted	410,134	401,099
Exercised	(251,063)	(165,169)
Expired	(89,550)	(50,002)
Ending balance, Outstanding	1,624,221	1,554,700
Exercisable	1,143,637
Weighted average exercise price
Beginning balance, Outstanding	$ 4.63	$ 3.12
Granted	12.28	9.27
Exercised	3.73	3.16
Expired	12.55	5.48
Ending balance, Outstanding	6.27	$ 4.63
Exercisable	$ 4.39
Weighted average remaining contractual life (years)	2 years 7 months 6 days	3 years
Weighted average remaining contractual life (years)	1 year 10 months 25 days
Outstanding, Aggregate intrinsic value	$ 7,925,643
Exercisable, Aggregate intrinsic value	$ 7,197,053

Stock Compensation (Details 1)	12 Months Ended
Stock Compensation (Details 1)	Dec. 31, 2019 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	1,624,221
Exercise Price \| $ / shares	$ 6.27
Options One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	175,799
Exercise Price \| $ / shares	$ 2.46
Expiration Date	Mar. 31, 2022
Options Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	41,668
Exercise Price \| $ / shares	$ 3.15
Expiration Date	Jun. 24, 2020
Options Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	210,520
Exercise Price \| $ / shares	$ 3.15
Expiration Date	Jul. 27, 2022
Options Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	470,000
Exercise Price \| $ / shares	$ 3.21
Expiration Date	Feb. 22, 2021
Options Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	105,836
Exercise Price \| $ / shares	$ 3.45
Expiration Date	Jul. 28, 2021
Options Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	100,006
Exercise Price \| $ / shares	$ 4.2
Expiration Date	Feb. 01, 2023
Options Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	8,336
Exercise Price \| $ / shares	$ 4.62
Expiration Date	Mar. 31, 2023
Options Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	8,336
Exercise Price \| $ / shares	$ 4.71
Expiration Date	Dec. 31, 2022
Options Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	8,000
Exercise Price \| $ / shares	$ 9.76
Expiration Date	Dec. 02, 2024
Options Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	139,000
Exercise Price \| $ / shares	$ 10.18
Expiration Date	Nov. 24, 2024
Options Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	8,336
Exercise Price \| $ / shares	$ 10.4
Expiration Date	Jun. 30, 2023
Options Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	11,800
Exercise Price \| $ / shares	$ 12.49
Expiration Date	Aug. 13, 2023
Options Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	6,000
Exercise Price \| $ / shares	$ 12.51
Expiration Date	Aug. 20, 2023
Options Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	10,000
Exercise Price \| $ / shares	$ 12.7
Expiration Date	Aug. 22, 2023
Options Fiveteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	15,000
Exercise Price \| $ / shares	$ 12.73
Expiration Date	Sep. 04, 2023
Options Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	14,084
Exercise Price \| $ / shares	$ 12.77
Expiration Date	Apr. 08, 2024
Options Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	30,500
Exercise Price \| $ / shares	$ 13.06
Expiration Date	Feb. 27, 2024
Options Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	16,000
Exercise Price \| $ / shares	$ 13.31
Expiration Date	Jun. 10, 2024
Options Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	40,000
Exercise Price \| $ / shares	$ 13.34
Expiration Date	Oct. 04, 2024
Options Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	29,000
Exercise Price \| $ / shares	$ 14.48
Expiration Date	Sep. 30, 2024
Options Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	16,000
Exercise Price \| $ / shares	$ 15.1
Expiration Date	May 23, 2024
Options Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	12,000
Exercise Price \| $ / shares	$ 15.32
Expiration Date	Jul. 15, 2024
Options Twenty Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	125,000
Exercise Price \| $ / shares	$ 15.4
Expiration Date	Oct. 16, 2023
Options Twenty Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	16,000
Exercise Price \| $ / shares	$ 15.51
Expiration Date	May 30, 2024
Options Twenty Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	7,000
Exercise Price \| $ / shares	$ 16.24
Expiration Date	Oct. 22, 2023

Stock Compensation (Details Textual) - USD ($)	12 Months Ended
Stock Compensation (Details Textual) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Stock Options (Textual)
Restricted shares	50,000	130,001
Restricted stock, value	$ 653,000	$ 546,007
Restricted stock vesting period	5 years
Expense remaining to be recognized related to options	$ 1,612,382
Stock options are exercisable term	1 year 9 months 18 days
Stock Compensation Plan [Member]
Stock Options (Textual)
Shares reserved for issuance	500,000
Share-based compensation plan, description	The Plan was amended several times since then to eventually increase the authorized shares to 2,500,000 as of December 31, 2019.
Options outstanding	1,624,221
Stock compensation remaining shares available to grant	236,614
Stock Options [Member]
Stock Options (Textual)
Compensation cost	$ 1,687,745	$ 1,317,904
Weighted average contractual life	1 year 10 months 25 days
Options exercisable	1,143,637
Restricted Stock [Member]
Stock Options (Textual)
Restricted shares	90,000
Restricted stock, value	$ 938,700
Restricted stock vesting period	4 years 3 months 19 days
Stock compensation recognized expense	$ 125,160
Compensation cost	$ 813,540

Warrants (Details) - Warrant [Member]	12 Months Ended
Warrants (Details) - Warrant [Member]	Dec. 31, 2018 $ / shares shares
Number of Shares Underlying Warrants
Beginning balance \| shares	348,194
Exercised \| shares	(348,194)
Ending balance \| shares
Weighted average exercise price
Beginning Balance \| $ / shares	$ 3.33
Exercised \| $ / shares	3.33
Ending Balance \| $ / shares

Leases (Details)

12 Months Ended

Dec. 31, 2019

USD ($)

Leases [Abstract]

Operating lease cost

$ 132,020

Short-term lease cost

84,935

^[1]

Total lease cost

$ 216,955

[1]	Short-term lease cost includes any lease with a term of less than 12 months.

Leases (Details 1)	Dec. 31, 2019 USD ($)
Leases [Abstract]
2020	$ 138,019
2021	140,367
2022	102,367
2023	99,209
2024	80,375
Thereafter	70,224
Total	630,561
Less: present value discount	66,377
Total lease liabilities	$ 564,184

Leases (Details Textual) - USD ($)	12 Months Ended
Leases (Details Textual) - USD ($)	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Leases (Textual)
Operating leases expires period	Nov. 30, 2022
Operating leases description	We also have a lease on office space in Cranbury, New Jersey, expiring in 2022 with monthly payments ranging from $3,008 to $3,158, as well as a lease of approximately $1,883 per month in Zagreb, Croatia expiring in 2022.
Operating lease, right of use asset	$ 559,863	$ 462,000
Operating lease related liabilities		$ 465,000
Weighted average remaining lease term	5 years 1 month 6 days
Weighted average discount rate	4.50%
Measurement of lease liabilities	$ 106,564
Payments on lease obligations	132,867
Amortization right of use assets	107,656
Minimum [Member]
Leases (Textual)
Operating leases rent payable	6,384
Maximum [Member]
Leases (Textual)
Operating leases rent payable	$ 6,688

Major Customers and Vendors (Details) - USD ($)	12 Months Ended
Major Customers and Vendors (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Revenue, Major Customer [Line Items]
Revenue	$ 24,598,274	$ 21,206,363
Customer A [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 3,883,589	$ 1,678,669
Revenue percentage	15.80%	7.90%
Customer B [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 2,801,748	$ 930,682
Revenue percentage	11.40%	4.40%
Customer C [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 2,533,766	$ 2,122,657
Revenue percentage	10.30%	10.00%
Customer D [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 1,349,214	$ 2,547,113
Revenue percentage	5.50%	12.00%
Customer E [Member]
Revenue, Major Customer [Line Items]
Revenue		$ 2,280,873
Revenue percentage	0.00%	10.80%
Partner A [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 1,315,706	$ 6,841,386
Revenue percentage	5.30%	32.30%
Partner B [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 9,210,347	$ 5,350,393
Revenue percentage	37.40%	25.20%
Partner C [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 4,051,217	$ 2,584,103
Revenue percentage	16.50%	12.20%
Partner D [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 1,007,573	$ 2,159,356
Revenue percentage	4.10%	10.20%

Major Customers and Vendors (Details Textual) - Customers	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Major Customers and Vendors (Textual)
No of customers	3
Revenue [Member] \| Four Key Partners [Member]
Major Customers and Vendors (Textual)
Concentration risk percentage total	10.00%	10.00%
Accounts Receivable [Member]
Major Customers and Vendors (Textual)
Concentration risk percentage total	10.00%
Customer One [Member] \| Revenue [Member]
Major Customers and Vendors (Textual)
Concentration risk percentage total	10.00%	10.00%
Customer One [Member] \| Accounts Receivable [Member]
Major Customers and Vendors (Textual)
Concentration risk percentage total	17.80%
Other Customer [Member] \| Revenue [Member]
Major Customers and Vendors (Textual)
Concentration risk percentage total	10.00%
Customer Two [Member] \| Accounts Receivable [Member]
Major Customers and Vendors (Textual)
Concentration risk percentage total	15.40%
Customer Three [Member]
Major Customers and Vendors (Textual)
Concentration risk percentage total	15.80%	7.90%
Customer Three [Member] \| Accounts Receivable [Member]
Major Customers and Vendors (Textual)
Concentration risk percentage total	13.30%

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Federal income tax benefit (expense) attributable to:
Current operations	$ 848,000	$ (48,000)
Acquisition costs	(143,000)
Change in fair value of contingent consideration	(133,000)
Other permanent items	29,000	(36,000)
Deferred Adjustment	(913,000)
Valuation allowance	1,209,960	84,000
Net provision for federal income tax	897,960
Current tax benefit (expense) - Federal
Deferred tax benefit (expense) - Federal
Adjustment of valuation allowance from business combination	897,960
Total tax benefit (expense) on income	$ 897,960

Income Taxes (Details 1) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Deferred tax asset attributable to:
Net operating loss carryover	$ 3,839,000	$ 2,290,000
Stock compensation	320,000	535,000
Intangible Assets		124,000
Other	36,000	3,000
Deferred tax asset	4,195,000	2,952,000
Deferred tax liabilities attributable to:
Fixed assets	(13,000)	(5,000)
Intangibles	(2,438,000)
Other	(16,000)	(9,000)
Valuation allowance	(1,728,000)	(2,938,000)
Deferred tax liability	(4,195,000)	(2,952,000)
Net deferred tax asset

Income Taxes (Details Textual) - USD ($)	12 Months Ended
Income Taxes (Details Textual) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Taxes (Textual)
Operating loss carryforwards	$ 18,300,000	$ 14,300,000
Operating loss expire, description	Expire from 2020 through 2037, and post-2017 losses in the amount of approximately $4 million that never expire.
Effective rate of tax expected	21.00%	21.00%

Commitments and Contingent Liabilities (Details)	12 Months Ended
Commitments and Contingent Liabilities (Details)	Dec. 31, 2019 USD ($)
Commitments and Contingent Liabilities (Textual)
Revenue share contracts, percentage	10.00%
Commitments for future minimum payments	$ 13,500,000
Minimum payments, description	Minimum payments are due in 2020, 2021, and 2022, in the amounts of $6.5 million, $5.5 million, and $2.0 million, respectively.

Retirement Plan (Details) - USD ($)	12 Months Ended
Retirement Plan (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Retirement Plan (Textual)
Defined benefit plan, description	The terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee's payroll.
Defined contribution plan, administrative expense	$ 126,557	$ 172,107

Subsequent Events (Details) - shares	1 Months Ended
Subsequent Events (Details) - shares	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Subsequent Events (Textual)
Shares Issued		14,600,579	12,038,618
Subsequent Event [Member]
Subsequent Events (Textual)
Options to purchase, exercise price	112,151
Shares Issued	35,032
Subsequent Event [Member] \| Board of Directors [Member]
Subsequent Events (Textual)
Number of shares authorized increased	3,000,000
Options to purchase of common stock	33,000
Options to new employees	38,000
Existing options that previously vested, description	The Company granted 84,746 shares of restricted common stock and options to purchase 233,049 shares of common stock to officers that vest over the balance of 2020.